What is Response Biomedical?
Founded in 1992 and headquartered in British Columbia, Response Biomedical Corp. specializes in the development, manufacturing, and commercialization of the RAMP system. This platform is engineered to provide lab-quality diagnostic performance at the point of care, facilitating rapid decision-making for healthcare providers in acute care settings. By bridging the gap between traditional laboratory testing and immediate clinical needs, the company addresses a vital efficiency bottleneck in patient management. Its core competencies lie in the integration of advanced biosensor technology with user-friendly diagnostic hardware, positioning the firm as a key player in the global diagnostics market. The company's focus on high-performance, rapid-turnaround testing remains a cornerstone of its value proposition to hospitals and emergency care facilities worldwide.
How much funding has Response Biomedical raised?
Response Biomedical has raised a total of $22.2M across 5 funding rounds:
Private Equity
$3.9M
Private Equity
$7.7M
Private Equity
$4.9M
Private Equity
$3.1M
Other Financing Round
$2.5M
Private Equity (2009): $3.9M, investors not publicly disclosed
Private Equity (2010): $7.7M, investors not publicly disclosed
Private Equity (2011): $4.9M, investors not publicly disclosed
Private Equity (2013): $3.1M, investors not publicly disclosed
Other Financing Round (2014): $2.5M backed by Silicon Valley Bank
Key Investors in Response Biomedical
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, private wealth management, brokerage & investment services, funds management, and business valuation services. The company was founded in 1983 and is headquartered in Santa Clara, California.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Response Biomedical?
With the successful acquisition of this latest financing, Response Biomedical is well-positioned to accelerate its product development roadmap and enhance its market penetration. The strategic deployment of these funds will likely focus on scaling manufacturing operations to meet increasing demand and potentially expanding the RAMP system's diagnostic menu. As the healthcare industry continues to prioritize decentralized testing and rapid clinical diagnostics, the company's ability to leverage this capital for technological innovation will be paramount. Future growth will likely hinge on the firm's capacity to maintain its competitive edge through rigorous clinical validation and the expansion of its commercial distribution networks, ensuring that its diagnostic solutions remain at the forefront of acute care innovation.
See full Response Biomedical company page
